It is no secret that GLP-1 receptor agonists have transformed the treatment of obesity and diabetes. The past 12 months have seen the GLP-1 landscape transform into something truly unrecognizable in previous years, with the global GLP-1 analogues market valued at US$47.4 billion in 2024.

With the next frontier of these blockbuster therapeutics well on its way to approval, the GLP-1 field is only going to grow, with novel combinations, indications, and formulations being explored. From MASH to Parkinson’s disease, there is potential for GLP-1s to become a ‘magic bullet’ across healthcare, only adding to the ever-increasing market value.

In this highly competitive market, Novo Nordisk and Eli Lilly currently lead with first-in-class GLP-1 therapies. However, the race is now focused on developing 'best-in-class' therapies that offer superior efficacy, particularly in weight loss, and are delivered through more convenient formats.

Despite significant progress, challenges remain. From oral formulations to agonist combinations, from muscle preservation to indication expansion, the question remains: who will be the next company to bring a GLP-1-based therapeutic to the market?

The 2nd GLP-1-Based Therapeutics Summit is your dedicated platform for leaders and decision-makers to connect, collaborate, and continue to transform healthcare as we know it through the development of GLP-1s.